New antifungal agents and preparations.
In neutropenic patients amphotericin B remains the drug of choice for the treatment of systemic fungal infections. On the basis of a superior efficacy in combination with a lower toxicity, the triazoles have superseded the older azoles. Regularly, amphotericin B and a triazole are used simultaneously without any evidence from clinical trials that such a strategy is safe and efficacious. Liposomal preparation, lipid complex or colloidal dispersion of amphotericin B have been produced successfully to reduce toxicity. However, there is only one small randomised study that hints at the superiority of liposomal amphotericin B over amphotericin B deoxycholate. Promising new agents like candins, sordarins, high dose oral terbinafine, the third generation azoles, and liposomal nystatin are under development. The first phase II study on voriconazole in the treatment of pulmonary aspergillosis has produced encouraging results. The major promise of the new candins lies in the activity against Candida species, including those resistant to the azoles and polyenes, and in a mechanism of action totally different from the established antifungals. Cytokines and colony stimulating factors are theoretically very promising but there are no clinical studies that warrant routine use.
De Pauw
B E
BE
Department of Hematology, University Hospital Nijmegen, P.O. Box 9101, 6500 HB Nijmegen, The Netherlands. b.depauw@hemat.azn.nl
D000935:Antifungal Agents / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D006801:Humans; D009181:Mycoses / Q000188:drug therapy*; D009503:Neutropenia / Q000150:complications*
D000935:Antifungal Agents